Early access to curative therapies is vital to support the clinical benefits they can provide to both patients and healthcare systems. Early access programs (EAPs) are a mechanism to facilitate faster patient access to curative therapies. With early access, EAPs can help improve patient outcomes and provide cost savings to healthcare systems. However, reimbursement through EAPs is vital so manufacturers are encouraged to pursue future research and innovation.
In this Insights, the authors provide an overview of the benefits of reimbursed access through EAPs for patients, healthcare systems, and manufacturers.
